Clik here to view.
IMCL-9815: Cetuximab plus radiotherapy superior to radiation alone in SCCHN
Barbara Burtness, MD, highlights data from the phase 3 IMCL-9815 trial, which demonstrated that patients with locally advanced squamous cell carcinoma of the head and neck benefitted more from...
View ArticleClik here to view.
Potential novel targets, therapies identified in patients with TRK, MET...
CHICAGO —Howard A. Burris, MD, chief medical officer at the Sarah Cannon Research Institute, highlights recent advances in defining novel targets, coupled with promising therapies to treat patients...
View ArticleClik here to view.
Antibody-drug conjugate shows promise for NSCLC, ovarian cancer
CHICAGO — Howard A. Burris, MD, chief medical officer at the Sarah Cannon Research Institute, offers his perspective on the phase 1 study of DNIB0600A, an antibody-drug conjugate targeting NaPi2b, in...
View ArticleClik here to view.
Prophylactic cranial irradiation decreased rate of cerebral metastasis in NSCLC
CHICAGO — Grace Dy, MD, associate professor in the department of medicine at Roswell Park Cancer Institute, offers her perspective on new data related to prophylactic cranial irradiation in the...
View ArticleClik here to view.
Stereotactic radiosurgery, chemotherapy regimen failed to improve OS in brain...
CHICAGO — Grace Dy, MD, associate professor in the department of medicine at Roswell Park Cancer Institute, discusses the results of a randomized phase 3 trial of stereotactic radiosurgery vs....
View ArticleClik here to view.
HPV-targeted immunotherapy shows promise for complete remission in metastatic...
CHICAGO — David O'Malley, MD, assistant professor of gynecologic oncology at Ohio State University James Cancer Hospital, highlights data from a phase 2 study which found that HPV-targeted...
View ArticleClik here to view.
Expert highlights advances in targeted therapies for gynecologic cancers
CHICAGO — In this video, David O'Malley, MD, assistant professor of gynecologic oncology at Ohio State University James Cancer Hospital, discusses the continued progress associated with targeted...
View ArticleClik here to view.
CD19-targeted T-cells show potential in B-ALL, allogeneic stem cell...
CHICAGO — Eunice Wang, MD, associate professor in the department of medicine at Roswell Park Cancer Institute, offers her perspective on the phase 2 study results which demonstrated that the use of a...
View ArticleClik here to view.
Flavopiridol, cytarabine, mitoxantrone regimen demonstrated promising...
CHICAGO — Eunice Wang, MD, associate professor in the department of medicine at Roswell Park Cancer Institute, highlights data from a randomized multicenter phase 2 study which demonstrated that...
View ArticleClik here to view.
RESPONSE 2: Ruxolitinib superior to best available therapy in polycythemia vera
CHICAGO — Eunice Wang, MD, associate professor in the department of medicine at Roswell Park Cancer Institute, discusses the results of the phase 3 RESPONSE 2 trial that showed ruxolitinib achieved...
View ArticleClik here to view.
E1A06: Lenalidomide provided superior QoL vs. thalidomide in multiple myeloma
CHICAGO — Saad Usmani, MD, FACP, director of clinical research in hematologic malignancies at Levine Cancer Institute, offers his perspective on the phase 3 E1A06 trial, that compared melphalan,...
View ArticleClik here to view.
Docetaxel plus ADT improved OS in metastatic prostate cancer
CHICAGO — Donald L. Trump, MD, FACP, president and CEO at Roswell Park Cancer Institute and HemOnc Today Editorial board member, discusses the results of an ECOG-led phase 3 randomized trial which...
View ArticleClik here to view.
Review highlights trends in hematologic malignancies at ASCO 2014
CHICAGO — John Sweetenham, MD, FRCP, FACP, executive medical director at Huntsman Cancer Institute and HemOnc Today‘s chief medical editor for hematology, discusses the latest research, trials, and...
View ArticleClik here to view.
Docetaxel combined with ADT improved survival in newly metastatic prostate...
CHICAGO — Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, president of Levine Cancer Institute at Carolinas HealthCare System and HemOnc Today‘s chief medical editor for oncology, highlights phase 3...
View ArticleClik here to view.
Experts note emerging value-driven health care trends at ASCO 2014
CHICAGO — HemOnc Today's chief medical editors John Sweetenham, MD, FRCP, FACP and Derek Raghavan, MD, PhD, FACP, FRACP, FASCO highlight several themes from the ASCO Annual Meeting that demonstrate a...
View Article
